Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | peptidylprolyl isomerase, putative | 0.0261 | 0.1132 | 0.5 |
Echinococcus multilocularis | L lactate dehydrogenase B chain | 0.0295 | 0.162 | 1 |
Chlamydia trachomatis | peptidyl-prolyl cis-trans isomerase | 0.0664 | 0.6827 | 0.5 |
Echinococcus granulosus | lactate dehydrogenase a | 0.0295 | 0.162 | 1 |
Wolbachia endosymbiont of Brugia malayi | malate dehydrogenase | 0.0295 | 0.162 | 0.5 |
Trypanosoma cruzi | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0261 | 0.1132 | 0.5 |
Echinococcus granulosus | lactate dehydrogenase protein | 0.0295 | 0.162 | 1 |
Toxoplasma gondii | peptidyl-prolyl cis-trans isomerase, FKBP-type domain-containing protein | 0.0664 | 0.6827 | 1 |
Echinococcus multilocularis | peptidyl prolyl cis trans isomerase FKBP4 | 0.0261 | 0.1132 | 0.6985 |
Schistosoma mansoni | immunophilin FK506 binding protein FKBP12 | 0.0261 | 0.1132 | 0.509 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.0295 | 0.162 | 1 |
Entamoeba histolytica | malate dehydrogenase, putative | 0.0295 | 0.162 | 1 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.0295 | 0.162 | 1 |
Schistosoma mansoni | malate dehydrogenase | 0.0295 | 0.162 | 1 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.0295 | 0.162 | 1 |
Trichomonas vaginalis | immunophilin, putative | 0.0261 | 0.1132 | 0.5 |
Plasmodium vivax | malate dehydrogenase, putative | 0.0295 | 0.162 | 1 |
Trypanosoma cruzi | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0261 | 0.1132 | 0.5 |
Mycobacterium ulcerans | FK-506 binding protein, peptidyl-prolyl cis-trans isomerase | 0.0261 | 0.1132 | 0.5 |
Schistosoma mansoni | immunophilin | 0.0261 | 0.1132 | 0.509 |
Trypanosoma brucei | peptidyl-prolyl cis-trans isomerase, putative | 0.0261 | 0.1132 | 0.5 |
Echinococcus granulosus | peptidyl prolyl cis trans isomerase FKBP1A | 0.0261 | 0.1132 | 0.6985 |
Trichomonas vaginalis | peptidylprolyl isomerase, putative | 0.0261 | 0.1132 | 0.5 |
Loa Loa (eye worm) | FKBP-type peptidyl-prolyl cis-trans isomerase-12 | 0.0261 | 0.1132 | 0.509 |
Echinococcus granulosus | lactate dehydrogenase a | 0.0295 | 0.162 | 1 |
Echinococcus multilocularis | peptidyl prolyl cis trans isomerase FKBP4 | 0.0225 | 0.0625 | 0.3859 |
Echinococcus multilocularis | fk506 binding protein | 0.0261 | 0.1132 | 0.6985 |
Plasmodium falciparum | L-lactate dehydrogenase | 0.0295 | 0.162 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0295 | 0.162 | 1 |
Trichomonas vaginalis | fk506-binding protein, putative | 0.0261 | 0.1132 | 0.5 |
Loa Loa (eye worm) | FKBP5 protein | 0.0261 | 0.1132 | 0.509 |
Schistosoma mansoni | L-lactate dehydrogenase | 0.0295 | 0.162 | 1 |
Giardia lamblia | 70 kDa peptidylprolyl isomerase, putative | 0.0261 | 0.1132 | 0.5 |
Echinococcus granulosus | peptidyl prolyl cis trans isomerase FKBP4 | 0.0225 | 0.0625 | 0.3859 |
Leishmania major | malate dehydrogenase, putative | 0.0295 | 0.162 | 1 |
Brugia malayi | lactate dehydrogenase. | 0.0295 | 0.162 | 1 |
Echinococcus multilocularis | lactate dehydrogenase protein | 0.0295 | 0.162 | 1 |
Plasmodium vivax | lactate dehydrogenase | 0.0295 | 0.162 | 1 |
Echinococcus granulosus | peptidyl prolyl cis trans isomerase FKBP4 | 0.0261 | 0.1132 | 0.6985 |
Schistosoma mansoni | immunophilin | 0.0261 | 0.1132 | 0.509 |
Trypanosoma cruzi | peptidyl-prolyl cis-trans isomerase, putative | 0.0261 | 0.1132 | 0.5 |
Plasmodium falciparum | malate dehydrogenase | 0.0295 | 0.162 | 1 |
Trypanosoma brucei | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0261 | 0.1132 | 0.5 |
Giardia lamblia | FKBP-type peptidyl-prolyl cis-trans isomerase | 0.0261 | 0.1132 | 0.5 |
Echinococcus granulosus | L lactate dehydrogenase B chain | 0.0295 | 0.162 | 1 |
Trypanosoma cruzi | peptidyl-prolyl cis-trans isomerase, putative | 0.0261 | 0.1132 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Relative SEAP activity (functional) | = 78 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in non-small cell lung cancer H1299 cell at 24 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 78 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in non-small cell lung cancer H1299 cell at 24 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 80 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in non-small cell lung cancer H1299 cell at 240.0 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 80 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in non-small cell lung cancer H1299 cell at 240.0 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 102 % | Compound was tested for cytomegalovirus or (pPCMV-SEAP) activity in immortalized hTERT-BJ1 at 2.4 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 102 % | Compound was tested for cytomegalovirus or (pPCMV-SEAP) activity in immortalized hTERT-BJ1 at 2.4 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 105 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in non-small cell lung cancer H1299 cell at 2.4 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 105 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in non-small cell lung cancer H1299 cell at 2.4 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 114 % | Compound was tested for cytomegalovirus or (pPCMV-SEAP) activity in immortalized hTERT-BJ1 at 24 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 114 % | Compound was tested for cytomegalovirus or (pPCMV-SEAP) activity in immortalized hTERT-BJ1 at 24 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 141 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in immortalized hTERT-BJI at 240.0 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 141 % | Compound was tested for cytomegalovirus or (pPCMV-SEAP) activity in immortalized hTERT-BJ1 at 240 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 141 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in immortalized hTERT-BJI at 240.0 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 141 % | Compound was tested for cytomegalovirus or (pPCMV-SEAP) activity in immortalized hTERT-BJ1 at 240 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 147 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in immortalized hTERT-BJI at 2.4 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 147 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in immortalized hTERT-BJI at 2.4 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 165 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in immortalized hTERT-BJI at 24 microM concentration | ChEMBL. | 12852760 |
Relative SEAP activity (functional) | = 165 % | Compound was tested for human telomerase reverse transcriptase-SEAP (hTERT-SEAP) activity in immortalized hTERT-BJI at 24 microM concentration | ChEMBL. | 12852760 |
Relative viability (functional) | = 70 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in non-small cell lung cancer H1299 cell at 240.0 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 70 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in non-small cell lung cancer H1299 cell at 240.0 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 93 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in immortalized hTERT-BJI at 24 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 93 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in immortalized hTERT-BJI at 24 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 94 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in immortalized hTERT-BJI at 2.4 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 94 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in immortalized hTERT-BJI at 2.4 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 97 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in non-small cell lung cancer H1299 cell at 24 uM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 97 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in non-small cell lung cancer H1299 cell at 24 uM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 100 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in immortalized hTERT-BJI at 240.0 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 100 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in immortalized hTERT-BJI at 240.0 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 103 % | pPCMV-SEAP (cytomegalovirus-SEAP) activity in immortalized hTERT-BJ1 at 240 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 103 % | pPCMV-SEAP (cytomegalovirus-SEAP) activity in immortalized hTERT-BJ1 at 240 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 104 % | pPCMV-SEAP (cytomegalovirus-SEAP) activity in immortalized hTERT-BJ1 at 24 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 104 % | pPCMV-SEAP (cytomegalovirus-SEAP) activity in immortalized hTERT-BJ1 at 24 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 106 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in non-small cell lung cancer H1299 cell at 2.4 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 106 % | hTERT-SEAP (Human telomerase reverse transcriptase-SEAP) activity in non-small cell lung cancer H1299 cell at 2.4 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 115 % | pPCMV-SEAP (cytomegalovirus-SEAP) activity in immortalized hTERT-BJ1 at 2.4 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Relative viability (functional) | = 115 % | pPCMV-SEAP (cytomegalovirus-SEAP) activity in immortalized hTERT-BJ1 at 2.4 microM concentration and level of cell viability determined in MTT assay | ChEMBL. | 12852760 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.